Managing skeletal related events resulting from bone metastases

Wilkinson, Anna N.; Viola, Raymond; Brundage, Michael

doi:10.1136/bmj.a2041

Cited by 37 publications

(37 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…(26,38,39) Bisphosphonate treatment is associated with an array of off-target effects including nephrotoxicity, osteonecrosis of the jaw, hypocalcemia, and flu-like symptoms (40,41,42) ; furthermore, the unwanted side effects of opioids and NSAIDs are well-documented. (7)(8)(9) Chronic pain treatments for advanced stage breast cancer have not been developed, and the failure of current pain therapies has generated a need for innovative and tailored approaches to managing cancer-pain.…”

Section: Discussionmentioning

confidence: 99%

“…NSAIDs, while effective at reducing inflammatory and musculoskeletal pains, (7) have been shown to aid in bone destruction and prevention of proper bone remodeling, thus decreasing bone strength in both animal models (8) and in human studies. (9) Recently, we demonstrated that sustained morphine not only intensifies tumor-induced pain but also accelerates tumor-induced bone destruction in a murine model of bone cancer. (10) Chronic opiate use results in a multitude of unbearable side effects including analgesic tolerance, somnolence, constipation, respiratory depression, and paradoxical states of hyperalgesia.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Disease modification of breast cancer–induced bone remodeling by cannabinoid 2 receptor agonists

Lozano-Ondoua

Hanlon

Symons-Liguori

et al. 2012

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

Most commonly originating from breast malignancies, metastatic bone cancer causes bone destruction and severe pain. Although novel chemotherapeutic agents have increased life expectancy, patients are experiencing higher incidences of fracture, pain, and drug-induced side effects; furthermore, recent findings suggest that patients are severely undertreated for their cancer pain. Strong analgesics, namely opiates, are first-line therapy in alleviating cancer-related pain despite the severe side effects, including enhanced bone destruction with sustained administration. Bone resorption is primarily treated with bisphosphonates, which are associated with highly undesirable side effects, including nephrotoxicity and osteonecrosis of the jaw. In contrast, cannabinoid receptor 2 (CB2) receptor-specific agonists have been shown to reduce bone loss and stimulate bone formation in a model of osteoporosis. CB2 agonists produce analgesia in both inflammatory and neuropathic pain models. Notably, mixed CB1/CB2 agonists also demonstrate a reduction in ErbB2-driven breast cancer progression. Here we demonstrate for the first time that CB2 agonists reduce breast cancer–induced bone pain, bone loss, and breast cancer proliferation via cytokine/chemokine suppression. Studies used the spontaneously-occurring murine mammary cell line (66.1) implanted into the femur intramedullary space; measurements of spontaneous pain, bone loss, and cancer proliferation were made. The systemic administration of a CB2 agonist, JWH015, for 7 days significantly attenuated bone remodeling, assuaged spontaneous pain, and decreased primary tumor burden. CB2-mediated effects in vivo were reversed by concurrent treatment with a CB2 antagonist/inverse agonist but not with a CB1 antagonist/inverse agonist. In vitro, JWH015 reduced cancer cell proliferation and inflammatory mediators that have been shown to promote pain, bone loss, and proliferation. Taken together, these results suggest CB2 agonists as a novel treatment for breast cancer–induced bone pain, in which disease modifications include a reduction in bone loss, suppression of cancer growth, attenuation of severe bone pain, and increased survival without the major side effects of current therapeutic options.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Disease modification of breast cancer–induced bone remodeling by cannabinoid 2 receptor agonists

Lozano-Ondoua

Hanlon

Symons-Liguori

et al. 2012

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

show abstract

“…Mais 2/3 des métastases sont osseuses, le plus souvent verté-brales et donc inextirpables. L'attitude thérapeutique est en ce cas médico-chirurgicale : antalgiques et anti-inflammatoires pour lutter contre la douleur et les phénomènes de compression nerveuse mais aussi biphosphonates et radiothérapie localisée ou parfois embolisation et radiofréquence [23,24]. En cas de signes de compression médullaire, un curettage décompressif suivi de vertébroplastie peut être proposé.…”

Section: Discussionunclassified

Histoire naturelle des paragangliomes malins de la tête et du cou. Analyse comparative

Médiouni

Wassef

Gimenez‐Roqueplo

et al. 2014

Annales françaises d'Oto-rhino-laryngologie et de Pathologie Ce

View full text Add to dashboard Cite

“…De même, une métastase hépatique unique peut-elle faire l'objet d'une résection réglée. Complète, cette exérèse chirurgicale permet des survies de longue durée [40][41][42][43].…”

Section: Indications Particulières : Les Formes Malignes Et/ou Sécrétunclassified

Radiothérapie et paragangliomes jugulaires

Huy¹

2014

Annales françaises d'Oto-rhino-laryngologie et de Pathologie Ce

View full text Add to dashboard Cite

Managing skeletal related events resulting from bone metastases

Cited by 37 publications

References 23 publications

Disease modification of breast cancer–induced bone remodeling by cannabinoid 2 receptor agonists

Disease modification of breast cancer–induced bone remodeling by cannabinoid 2 receptor agonists

Histoire naturelle des paragangliomes malins de la tête et du cou. Analyse comparative

Radiothérapie et paragangliomes jugulaires

Contact Info

Product

Resources

About